secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001077183-24-000106
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q2 revenue $165M (+12% YoY); raises FY2024 EBITDA guidance to $33-37M
--------------------------------------------------------------------------------

- Q2 revenue $165M (+12% YoY); net loss narrowed 23% to $19M.
- Adjusted EBITDA $11M (+630% YoY) vs -$2M in prior-year quarter.
- Clinical Services revenue $141M (+15% YoY); Advanced Diagnostics $23M (-3%).
- FY2024 guidance raised: revenue $655-667M (from $650-660M); adj. EBITDA $33-37M (from $21-24M).
- Cash and marketable securities $388M at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718324000106/0001077183-24-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718324000106/neo-20240729.htm
  HTML page:      https://secwatch.observer/filing/0001077183-24-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer